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Abstract: Chagas disease is usually caused by tropical infection with the insect-transmitted protozoan
Trypanosoma cruzi. Currently, Chagas disease is a major public health concern worldwide due
to globalization, and there are no treatments neither vaccines because of the long-term nature
of the disease and its complex pathology. Current treatments are limited to two obsolete drugs,
benznidazole and nifurtimox, which lead to serious drawbacks. Taking into account the urgent need
for strict research efforts to find new therapies, here, we describe the in vitro and in vivo trypanocidal
activity of a library of selected forty-eight selenocyanate and diselenide derivatives that exhibited
leishmanicidal properties. The inclusion of selenium, an essential trace element, was due to the well-
known extensive pharmacological activities for selenium compounds including parasitic diseases as
T. cruzi. Here we present compound 8 as a potential compound that exhibits a better profile than
benznidazole both in vitro and in vivo. It shows a fast-acting behaviour that could be attributed to
its mode of action: it acts in a mitochondrion-dependent manner, causing cell death by bioenergetic
collapse. This finding provides a step forward for the development of a new antichagasic agent.
Keywords: American trypanosomiasis; chagas disease; chemotherapy; drug discovery; neglected
tropical diseases; screening cascade; selenium derivatives; target product profile; Trypanosoma cruzi
1. Introduction
Chagas disease (CD), also known as American trypanosomiasis, is caused by tropical
infection with the insect-transmitted protozoan parasite Trypanosoma cruzi. CD is an
important public health problem in Latin America since it is a life-long and life-threatening
infection, being the major cause of morbimortality in many endemic regions: a total of 6 to
7 million people are infected, and the disease causes about 14 thousand deaths annually.
Hematophagous triatomines (vectors) are the principal route of transmission, although
congenital route, transmission route from donors to transplant or transfusion recipients,
and oral route involving parasite-contaminated food and drink are also important [1–4].
T. cruzi infection is far from innocuous and, in mammal hosts, it is an obligate intra-
cellular parasite for its replication, which can infect most nucleated cells [5,6]. During
the initial acute stage of the disease, which occurs 2–8 weeks post-infection in humans,
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parasite become widely disseminated in tissues and organs and can be detected in the
bloodstream, and CD generally manifests as a mild febrile illness. Following suppression
of the acute stage by the adaptive immune response [7,8], the disease progresses to a long-
lasting asymptomatic chronic stag, which is characterized by an extremely low parasite
burden. However, ~30% of those infected will advance to a symptomatic stage, developing
pathology such as cardiomyopathy and digestive tract megasyndromes, outcomes for
which there are few therapeutic options [9–11].
Due to the long-term nature of CD and its complex pathology, the development of
vaccines against T. cruzi is a challenging goal. Recombinant protein-, DNA-, and viral vector-
based vaccines have recently been shown to be protective in mouse models. However,
new challenges have to be addressed, such as better endpoints, safety issues and trial
design [12–14]. The nitroheterocyclic drugs benznidazole (BZN) and nifurtimox (NFX) are
the front-line chemotherapy used to treat T. cruzi infections for more than 50 years, although
treatment failures are frequently reported, in addition to a range of toxic side-effects and
extended treatment length [14–19]. Furthermore, the well-known cross-resistance, since
both drugs require to be activated within the parasite by the same mitochondrial type 1
nitroreductase (TcNTR-1) [20,21], and the natural variation in susceptibility to drugs due to
the extreme diversity of species [22], along with the World Health Organization (WHO)
lists CD as one of the most neglected tropical diseases, make crucial the international effort
aimed at developing new drugs against Chagas disease.
Taking into account the urgent need for new drugs with improved efficacy, tolerability
and safety, here, we describe the in vitro and in vivo trypanocidal activity of a library
of selected forty-eight selenocyanate and diselenide derivatives [23–25] that exhibited
leishmanicidal properties. These chemical moieties have been decorated with various
substituted aromatic and heteroaromatic rings. Therefore, we explored the importance of
the sulfonamide group [23], considering the interest of this motif as linker in described
compounds for treatment of trypanosomatid infections [26]. The inclusion of selenium, an
essential trace element, was due to the well-known extensive pharmacological activities
for selenium compounds including parasitic diseases as T. cruzi [27]. On the other hand,
it has been demonstrated the interference of selenium in redox processes of the parasite.
Some selenium compounds have demonstrated proved efficacy as trypanothione reductase
inhibitors the major reductase of trypanosomatids that contributes to redox homeostasis
suggesting that its mode of action involves interference with the intracellular redox balance.
In addition, most selenoproteins are redox enzymes containing a catalytic selenocysteine
residue. The named “TriTryps” selenoproteome consists of a trypanosomatid specific
selenoprotein (Seltryp) and two selenoproteins present in other lineages: SelT and SelK.
Seltryp possesses two rhodanese domains and an N-terminal selenocysteine containing
redox motif [28,29].
2. Results and Discussion
2.1. In Vitro Biological Evaluation
Initially, the in vitro screening for the forty-eight derivatives was performed on epi-
mastigote form using benznidazole (BZN) as reference drug (Table S1). Twenty-nine of the
tested compounds displayed similar effectiveness than the reference with IC50 ranged from
0.9 to 18.4 µM. In parallel, and considering the importance of the selectivity index (SI), their
cytotoxicity in Vero cells was determined. The SI for the drugs was determined by the ratio
of the IC50 of Vero cells over the IC50 obtained for the corresponding form of the parasite.
The cytotoxicity values registered against Vero indicated that the activity of many of these
derivatives was not specific against T. cruzi as it is showed in the SI. In this context, and
with the most exigent criteria established by the literature [15,30–33], we considered for
further progression the compounds that complied with IC50 ≤ 10 µM, SI ≥ 10 and 4-fold
more selective than the reference (compounds 8, 10, 11, 15, 20, 21, 43, 46, and 47).
Taking into account that the parasite forms relevant to human infection are trypo-
mastigotes and intracellular amastigotes, the derivatives that exhibited the better profiles
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were tested in these forms (Table 1). This approach is in accordance with the Drugs for
Neglected Diseases Initiative guidelines (DNDi) [30]. All of them were more active than
BZN in both forms with IC50 values between 0.5 and 4.2 µM in amastigotes and 0.9 and
4.5 µM in trypomastigotes. However, it was important to ensure the potential suitability
of the compounds analyzing the SI. Good results were found for the hit compounds in
all parasite forms tested with SI values exceeding the SI of BZN. The most highlighted
were 8 and 10 which contained the diselenide moiety. Particularly 10 presented a SI over
15, 11, and 11 times its registered by the reference for epimastigote, amastigote and BTs,
respectively. Derivative 15, with the selenocyanate entity, showed SI over 4, 4, and 2 times
respect to control. We report herein three potential candidates with biological activity
against these three trypanosomatids forms that deserved further in vivo investigations.
Table 1. Activity of benznidazole and compounds tested against the three developmental forms of Trypanosoma cruzi,
toxicity on mammalian Vero cells, and selectivity index.
Comp
Activity IC50 (µM) a Toxicity IC50 (µm) b
Vero Cell
Selectivity Index c
Epimast. Amast. Trypomast. Epimast. Amast. Trypomast.
BZN 16.9 ± 1.8 8.3 ± 0.7 12.4 ± 1.1 80.4 ± 7.1 5 10 7
8 1.9 ± 0.1 0.8 ± 0.2 1.5 ± 0.3 44.3 ± 2.7 23 (5) 55 (6) 30 (4)
10 1.8 ± 0.2 1.2 ± 0.2 1.7 ± 0.3 134.6 ± 6.3 75 (15) 112 (11) 79 (11)
11 3.0 ± 0.4 3.1 ± 0.1 4.5 ± 0.6 61.3 ± 3.7 20 (4) 20 (2) 14 (2)
15 0.9 ± 0.1 0.5 ± 0.0 1.3 ± 0.3 17.9 ± 1.0 20 (4) 36 (4) 14 (2)
20 1.3 ± 0.2 1.0 ± 0.1 0.9 ± 0.0 16.4 ± 0.5 13 (3) 16 (2) 18 (3)
21 1.0 ± 0.2 0.8 ± 0.1 0.9 ±0.1 21.7 ± 1.8 22 (4) 27 (3) 24 (3)
43 5.1 ± 0.6 4.2 ± 0.7 3.7 ± 0.2 66.9 ± 6.2 13 (3) 16 (2) 18 (3)
46 2.7 ± 0.8 2.3 ± 0.1 2.0 ± 0.3 48.6 ± 3.5 18 (4) 21 (2) 24 (3)
47 3.6 ± 0.3 3.0 ± 0.4 3.8 ± 0.4 44.7 ± 3.0 12 (2) 15 (2) 12 (2)
a Inhibition concentration 50 (IC50), concentration (µM) required to inhibit 50% population, determined using GraphPad Prism 6. b Towards
Vero cells. c Selectivity index (SI), IC50 Vero cells/IC50 developmental forms of the parasite. Values are the means of three separate
determinations ± standard deviation. In brackets: number of times that compounds exceed the reference drug SI. BZN, benznidazole.
Before going ahead on in vivo trials, the in vitro infection rate and the average number
of amastigotes per Vero cell were also measured at 2 days intervals for 10 days after treating
the infected cultures with BZN and potential candidates (8, 10, and 15) (Figure 1) at
ICH25 concentrations resulting from amastigotes screening. In short, potential candidates
produced a decrease in both infection rate and number of amastigotes per cell in a time-
dependent manner, showing activity from the first 48 h of treatment. All these potential
candidates can be considered as fast-acting compounds since they showed activity from
the beginning of the treatment, such as BZN (a drug considered to be fast-acting) [34].
Fast-acting drugs are urgently needed, and this feature is an additional advantage since
they can eliminate the parasite in a few doses [35].
2.2. In Vivo Biological Evaluation
Currently, clinical drugs present variable activity in the acute and chronic phases of
CD, and the effectiveness of current treatments—especially during chronic CD—is not
as effective as they should be [15]. For this reason, and based on the previous in vitro
assays, compounds 8, 10, and 15 were tested to determine their effectiveness in both phases
according to the timeline stablished in the Scheme 1. It should be noted that most in vivo
trials have focused on acute CD because of the simplicity of monitoring parasitic load [36];
however, the ability to cure chronic CD is the major demand from a clinical viewpoint [37].
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Alternatively, mice were treated once daily for 5 consecutive days—it is defined that a
compound showing a reasonable parasitemia reduction following 5 days of treatment can
be considered a lead compound [15]—at a subcurative dose of BZN of 20 mg·Kg−1·day−1—
so that the trials could demonstrate whether the potential candidates are more effective (or
not) than the reference drug.
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Firstly, the parasitemia levels were determined by counting BTs during the acute
CD (Figure 2A). Significant differences were observed between untreated (control) and
BZN-treated mice, which showed a remarkable parasitemia reduction even at a subcurative
dose. Interestingly, the trypanocidal activity was even stronger for compound 8; its effect
was evident from the beginning of the treatment, showing an undetectable parasitemia on
the 12th dpi, being the lowest subsequently, and eliminating or depleting it to undetectable
levels on the 46th dpi (that is, 7 days before the parasitemia of untreated and BZN-treated
mice). Long-term treatment could be carried out in order to reach higher efficiency. A slight
activity was observed for compound 10, and non-significant differences were observed
between untreated and compound 15-treated mice.
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control, (+) PCR positive control, (1–7) organs/tissues PCR: (1) adipose, (2) bone marrow, (3) brain, (4) esophagus, (5) heart,
(6) lung, (7) muscle.  1/3 of the corresponding organ/tissue PCR products showed 300 bp band on electrophoresis; * 2/3
of the corresponding organ/tissue PCR products showed 300 bp band on electrophoresis.
Secondly, the experimental cure was determined using a double checking widely used
in in vivo trypanocidal trials. This double checking—based on immunosuppression and
PCR (Figure 2B,C, respectively)—was performed to evaluate the treatment effectiveness
and the disease extent in both acute and chronic CD at the end of the in vivo timeline. The
mice whose parasitemia and PCR remain negative after immunosuppression are considered
cured [38–40].
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Immunosuppression enhances the reactivation of any residual infection, which is
proportional to the parasite survival rate [41]. Figure 2B shows the reactivation of infection
for each mice group compared to untreated (control) mice. As expected, BZN exhibited
higher efficacy in chronic CD than in acute CD (reactivations of 81% and 68% in acute and
chronic CD, respectively); it is widely known that BZN is more effective in chronic than in
acute CD in mice models [38,42], probably because the parasitic load is low and limited
to a few locations. Interestingly, compound 8 showed higher efficacy than BZN in both
acute and chronic CD, with reactivations of 67% and 44%, respectively. Once again, a light
activity was observed for compound 10, and non-significant differences were observed
between untreated and compound 15-treated mice.
To assess the efficacy of potential candidates by confirming the absence of infection in
the target locations, PCR was carried out at the end of the in vivo timeline (Figure 2C). PCR
was positive in seven organs/tissues for the untreated (control) mice groups in both phases,
showing the presence of the typical nested amastigotes of the chronic CD. BZN-treated
mice exhibited 2/7 and 3/7 negative PCR (parasite-free locations) in acute and chronic
CD, respectively. Consistent with previous parasitemia and reactivation results, compound
8-treated mice showed the highest number of negative PCR after treatment in both acute
and chronic CD (3/7 and 4/7 parasite-free sites, respectively).
At observed, compound 8 exhibited higher efficacy than BZN at the tested doses in
both acute and chronic CD after the double checking of experimental cure, confirming it as
a potential candidate for further preclinical research.
Otherwise, the immune status of the mice was evaluated—through the titer of total
anti-T. cruzi IgG and the splenomegaly (Figure S1)—since it is a characteristic linked to the
parasite load and the effectiveness ascribed to the potential candidates [40,43]. In summary,
BZN- and compound 8-treated mice showed significant reduction in both the IgG levels
and the splenomegaly, excluding the IgG levels of chronic CD (its samples coming from
mice that have undergone a natural history of acute untreated CD). It is interesting to
note that compound 8-treated mice showed very low IgG levels from the beginning to the
end of the in vivo timeline in the acute treatment, becoming similar to the cut off value
(uninfected mice). Overall, these results confirm the previous results, and demonstrate
the in vivo trypanocidal activity of compound 8. Slight or non-significant reductions were
observed for compound 10- and compound 15-treated mice in most cases. It has to be
mentioned that the samples obtained after IS do not reflect data indicating infection rates,
but confirm the IS suffered by the mice.
Finally, biochemical analyses were performed to assess the toxicity associated to the
treatment of compound 8. Kidney, heart and liver biochemical markers were measured,
including values from uninfected and BZN-treated mice (Table S2). Most of the biochemical
markers were disturbed 2 days after treatment for both BZN and compound 8, but returned
to near-normal levels over time. Notably, none of the mice died nor lost more than 10%
body mass after treatment. The low toxicity allows compound 8 to be tested at higher
doses, establishing an improved treatment schedule based on pharmacokinetics in order to
reach a total parasite clearance.
2.3. Mode of Action Studies
The mode of action studies were initiated at the glycolytic and mitochondrial levels,
since fast-acting and trypanocidal activities exhibited by the potential candidates could be
explained by a bioenergetic collapse. It is widely known that T. cruzi catabolizes glucose at
a high rate, excreting to the medium incompletely oxidized metabolites such as pyruvate
and succinate, among others [44,45]. Hence, these metabolites were qualitatively and
quantitatively analyzed by 1H RMN and compared with those found for untreated parasites
(Figure 3A). As shown, metabolites from compound 8- and compound 10-treated parasites
were not substantially altered (<10% variation). However, the excretion of all metabolites
from compound 15-treated parasites was strikingly increased concerning the corresponding
untreated parasites. Succinate and pyruvate were the most increased excretions, which
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are likely to be result of a decreased ATP synthesis due to mitochondrial dysfunction.
This ATP deficit is balanced by the so-called Crabtree effect, that is, by an increase in the
activity of the glycolytic pathway [46]. Alternatively, an increase in succinate could also
be a consequence of redox stress produced by Fe-SOD inhibition [47]. Consequently, the
hypothetical mitochondrial dysfunction and enzyme Fe-SOD inhibition was evaluated.
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Mitochondrial integrity was evaluated by flow cytometry after staining the parasites
with Rho (Figure 3B). KCN-treated parasites were included as control samples with fully
depolarized mitochondria [48]. It is widely known that BZN causes, among others, res-
piratory chain inhibition through its transformation to highly reactive metabolites [49],
decreasing the mitochondrial membrane potential (35.4%). All tested compounds caused
a considerable depolarization in the mitochondrial membrane potential, being similar o
even higher than those caused by BZN (from 30.3 to 47.8%). Therefore, the glycolytic
alteration observed by compound 8 could be explained by a mitochondrial dysfunction
and an ATP deficit. Overall, since the mitochondrion balances the NADH/NAD+ and
ATP/ADP ratios and plays a crucial role in cell death decisions [50–52], the cidal mode
of action of these compounds could be construed as a bioenergetic collapse before cell
death in a mitochondrion-dependent manner. This mode of action could be the cause of
the fast-acting trypanocidal activities of these compounds.
Alternatively, mitochondrial dysfunctions can cause a reduction in nucleic acid lev-
els [44], which were determined by flow cytometry (Figure S2). Remarkably, all treated
parasites showed higher reductions than BZN in nucleic acid levels (from 44.9 to 69.5% for
compounds, and 22.4% for BZN). Since the reduction in nucleic acids could also be due to
random degradation attributed to necrosis [51], the biological consequences of compounds
were more than probably due to a cidal mode of action.
Finally, Fe-SOD enzyme inhibition assays were performed. Fe-SOD is one of the
most relevant therapeutic targets for CD because of its structural/biochemical differences
with the human CuZn-SOD [53] and its protective effects against oxidative stress [54].
SOD inhibition curves are shown in Figure 3C. Compounds 8 and 10 were selective for
the parasitic enzyme Fe-SOD, reaching 100% inhibition at 100 µM. However, their IC50
values are too high to attribute trypanocidal activity to the inhibition of this enzyme.
Compound 15 showed no inhibitory activity.
3. Materials and Methods
3.1. Chemistry
The compounds (Figure 4) were prepared using the previously reported procedures.
Briefly, selenocyanate derivatives (compounds 1, 3, 5, 7, 9, 11, 13, 15, 16, 17, 18, 23, 24, 26, 27,
29, 30, and 31) were obtained from the corresponding halides by nucleophilic substitution in
the presence of potassium selenocyanate (KSeCN) in acetone. The diselenide (compounds 2,
4, 6, 8, 10, 12, 14, 19, 20, 21, 22, 25, 28, and 32) were prepared by reduction of the correspond-
ing selenocyanates with sodium borohydride in ethanol. Finally, the selenosulfonamides
(compounds 33–48) were synthesized by reaction of 4,4’-diaminodiphenyldiselenide with
different sulfonyl chlorides in ethyl ether.
3.2. In Vitro Activity Assays
3.2.1. Screening against Extracellular Epimastigotes
Trypanocidal activity against epimastigotes of T. cruzi Arequipa strain (MHOM/Pe/
2011/Arequipa, discrete typing unit V) was tested as previously described [55,56]. In
short, 5 × 105 epimastigotes·mL−1 were treated by adding the tested compounds at a
concentration range from 100 to 0.2 µM in 96-well microplates (200 µL·well−1) for 48 h.
Subsequently, resazurin sodium salt (Sigma-Aldrich) was added to be incubated for further
24 h. Finally, the absorbance was measured, and the trypanocidal activity was expressed as
the IC50 (inhibitory concentration 50) using GraphPad Prism 6 software. Each compound
concentration was tested in triplicate in three independent experiments.
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3.2.2. Cytotoxicity Test
Mammalian Vero cells (EACC No. 84113001), cultured as previously reported [57],
were used to determine the cytotoxicity of the tested compounds [56]. In hort,
1.25 × 104 Vero cells·mL−1 were treated by adding the compounds at a concentration
range from 400 to 1 µM in 96-well microplat s (200 µL·well−1) at 37 ◦C for 48 h. S bse-
quently, resazuri sodium salt (Sigma-Aldrich) was added to be incubated for further 24 h.
Finally, cell viability was determined following the same procedur as descr bed to assess
the trypanocidal activity in the epimastigotes. Each compound concentration was tested in
triplicate in three independent experiments.
3.2.3. Screening against Intracellular Amastigotes and Infected Cells
Tr panocidal activity against amastigotes was determined according to the literature
reported previously [42]. In short, culture derived trypomastigotes (obtained as previously
described [56]) were used to infect 1 × 104 Vero cells·well−1 in 24-well microplates with
rounded coverslips at a multiplicity of infection (MOI) ratio of 10:1 for 24 h. After that, non-
phagocyted trypomastigotes were washed and the plates were treated by adding the tested
compounds at a concentration range from 50 to 0.1 µM in 500 mL·well−1 at 37 ◦C in 95%
humidified air and 5% CO2 atmosphere. After 72 h of incubation, the trypanocidal effect
was determined based on the number of amastigotes and infected cells in methanol-fixed
and Giemsa stained preparations by analyzing 500 host cells randomly distributed in micro-
scopic fields, and the activity was expressed as the IC50 using GraphPad Prism 6 software.
Each compound concentration was tested in triplicate in four separate determinations.
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3.2.4. Screening against Bloodstream Trypomastigotes
2 × 106 Bloodstream trypomastigotes (BTs), obtained by cardiac puncture from in-
fected BALB/c mice as previously described [56], were treated by adding the tested com-
pounds at a concentration range from 50 to 0.1 µM in 96-well microplates (200 µL·well−1)
at 37 ◦C. After 24 h of treatment, resazurin sodium salt (Sigma-Aldrich) was added to be
incubated for further 4 h [42]. Finally, trypanocidal activity was determined following the
same procedure as described to assess the trypanocidal activity in the epimastigotes. Each
compound concentration was tested in triplicate in three independent experiments.
3.3. In Vivo Activity Assays on BALB/c Mice
3.3.1. Ethics Statement
All animal work (protocols and procedures, Scheme 1) was performed under RD53/
2013 and approved by the Ethics Committee on Animal Experimentation (CEEA) of the
University of Granada, Spain. Female BALB/c mice aged 10–12 weeks and ~20 g were
maintained under standard conditions.
3.3.2. Infection and Treatment
Infection was carried out by intraperitoneal inoculation of 5 × 105 BTs of T. cruzi per
mouse in 0.2 mL PBS [56]. The mice were treated by oral route (~200 µL) once daily for 5
consecutive days. The treatment for mice treated in the acute and chronic phases began
when the infection was confirmed (9th day post-infection (dpi)) and was established that
the animals had entered the chronic phase (100th dpi), respectively [42].
The mice were divided into six groups (n = 3 per group): 0, negative control group
(uninfected and untreated mice); I, positive control group (infected and untreated mice);
II, BZN group (mice infected and treated with BZN); III, 8 group (mice infected and treated
with 8); IV, 10 group (mice infected and treated with 10); V, 15 group (mice infected and
treated with 15). The tested compounds and BZN were prepared at 2 mg·mL−1 in an
aqueous suspension vehicle containing 5% (v/v) DMSO and 0.5% (w/v) hydroxypropyl
methylcellulose, as previously reported [38]. Therefore, doses of 20 mg·kg−1 per day were
administered for 5 consecutive days, and vehicle only was administered in the negative
and positive control groups.
3.3.3. Screening Assays on Mice
All in vivo assays for the evaluation of compounds in the acute and chronic CD
(Scheme 1)—monitoring of parasitemia [56], immunosuppression [58], PCR [59,60],
ELISA [56], and clinical analysis [56]—were performed as previously described. PCR
was based on the Spliced Leader (SL) intergenic region sequence of T. cruzi (for detailed
description, see literature reported previously).
3.4. Mode of Action Studies
3.4.1. H Nuclear Magnetic Resonance (NMR) Analysis of Excreted Metabolites
5 × 105 epimastigotes·mL−1 of T. cruzi Arequipa were treated by adding the tested
compounds at IC25 concentrations in 25 cm2 cell culture flasks at 28 ◦C for 72 h. Un-
treated controls were also included. Cultures were then centrifuged and filtered, and the
metabolites of the supernatants were analyzed using a 1H NMR spectrometer (VARIAN
DIRECT DRIVE 500 MHz Bruker) with AutoX probe, D2O as solvent and 2,2-dimethyl-2-
silapentane-5-sulphonate as the reference signal [61]. Chemical shifts were expressed in
parts per million (ppm), and analyses were conducted as previously reported [62].
3.4.2. Flow Cytometry Analysis of Mitochondrial Membrane Potential and Nucleic
Acid Levels
The untreated and treated epimastigotes of T. cruzi described in the NMR analysis
were collected by centrifugation, washed three times in PBS and stained with 10 mg·mL−1
rhodamine 123 (Rho) (Sigma-Aldrich) or acridine orange (AO) (Sigma-Aldrich) dyes in
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0.5 mL PBS for 20 min at 28 ◦C [63]. Control epimastigotes with a fully depolarized
mitochondrion were obtained by incubation for 40 min with 10 mM KCN prior to Rho
loading [48]. Non-stained parasites were also included. After elapsed time, epimastigotes
were immediately processed and analyzed by flow cytometry as previously reported [62].
3.4.3. SOD Enzymatic Inhibition Analysis
Excreted Fe-SOD protein—obtained and quantified as previously described [64]—
and commercial Cu/Zn-SOD from human erythrocytes (Sigma-Aldrich) were exposed to
the tested compounds at a concentration range from 100 to 0.1 µM to determine in vitro
activities using the method previously described [65].
3.5. Statistical Analyses
Statistical analyses were performed by using SPSS software (v. 21, IBM). The t-test for
paired samples was used to verify whether there were differences between the assays used,
with a value of p < 0.05 considered statistically significant and with a 95% confidence level.
In addition, statistical studies based on contingency tables (prevalence) were conducted.
4. Conclusions
A library of forty-eight selenocyanate and diselenide derivatives were screened against
T. cruzi. We identified compound 8 as a promising alternative that represents a step
forward in the development of new drugs against CD in both acute and chronic infection.
Compound 8 shows higher trypanocidal activity against the three morphological forms,
lower toxicity, and higher efficacy after in vivo treatment than the reference drug BZN. In
addition, compound 8 shows a fast-acting behaviour that could be attributed to its mode
of action: it acts in a mitochondrion-dependent manner, causing cell death by bioenergetic
collapse due to mitochondrial dysfunction. It is worth considering long-term treatment,
or even combined therapies, because of its lack of toxicity with the aim of achieving a
sterile cure.
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